Literature DB >> 20007295

Glucuronidation of dihydrotestosterone and trans-androsterone by recombinant UDP-glucuronosyltransferase (UGT) 1A4: evidence for multiple UGT1A4 aglycone binding sites.

Jin Zhou1, Timothy S Tracy, Rory P Remmel.   

Abstract

UDP-glucuronosyltransferase (UGT) 1A4-catalyzed glucuronidation is an important drug elimination pathway. Although atypical kinetic profiles (nonhyperbolic, non-Michaelis-Menten) of UGT1A4-catalyzed glucuronidation have been reported occasionally, systematic kinetic studies to explore the existence of multiple aglycone binding sites in UGT1A4 have not been conducted. To this end, two positional isomers, dihydrotestosterone (DHT) and trans-androsterone (t-AND), were used as probe substrates, and their glucuronidation kinetics with HEK293-expressed UGT1A4 were evaluated both alone and in the presence of a UGT1A4 substrate [tamoxifen (TAM) or lamotrigine (LTG)]. Coincubation with TAM, a high-affinity UGT1A4 substrate, resulted in a concentration-dependent activation/inhibition effect on DHT and t-AND glucuronidation, whereas LTG, a low-affinity UGT1A4 substrate, noncompetitively inhibited both processes. The glucuronidation kinetics of TAM were then evaluated both alone and in the presence of different concentrations of DHT or t-AND. TAM displayed substrate inhibition kinetics, suggesting that TAM may have two binding sites in UGT1A4. However, the substrate inhibition kinetic profile of TAM became more hyperbolic as the DHT or t-AND concentration was increased. Various two-site kinetic models adequately explained the interactions between TAM and DHT or TAM and t-AND. In addition, the effect of TAM on LTG glucuronidation was evaluated. In contrast to the mixed effect of TAM on DHT and t-AND glucuronidation, TAM inhibited LTG glucuronidation. Our results suggest that multiple aglycone binding sites exist within UGT1A4, which may result in atypical kinetics (both homotropic and heterotropic) in a substrate-dependent fashion.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20007295      PMCID: PMC2835394          DOI: 10.1124/dmd.109.028712

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  38 in total

Review 1.  Structural and functional studies of UDP-glucuronosyltransferases.

Authors:  A Radominska-Pandya; P J Czernik; J M Little; E Battaglia; P I Mackenzie
Journal:  Drug Metab Rev       Date:  1999-11       Impact factor: 4.518

2.  Substrate inhibition kinetics for cytochrome P450-catalyzed reactions.

Authors:  Y Lin; P Lu; C Tang; Q Mei; G Sandig; A D Rodrigues; T H Rushmore; M Shou
Journal:  Drug Metab Dispos       Date:  2001-04       Impact factor: 3.922

3.  Triazolam substrate inhibition: evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site.

Authors:  M L Schrag; L C Wienkers
Journal:  Adv Exp Med Biol       Date:  2001       Impact factor: 2.622

Review 4.  Human UDP-glucuronosyltransferases: metabolism, expression, and disease.

Authors:  R H Tukey; C P Strassburg
Journal:  Annu Rev Pharmacol Toxicol       Date:  2000       Impact factor: 13.820

5.  In vitro and in vivo glucuronidation of midazolam in humans.

Authors:  Ruth Hyland; Toby Osborne; Anthony Payne; Sarah Kempshall; Y Raj Logan; Khaled Ezzeddine; Barry Jones
Journal:  Br J Clin Pharmacol       Date:  2009-04       Impact factor: 4.335

6.  Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism.

Authors:  K E Kenworthy; S E Clarke; J Andrews; J B Houston
Journal:  Drug Metab Dispos       Date:  2001-12       Impact factor: 3.922

7.  In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin.

Authors:  M B Fisher; K Campanale; B L Ackermann; M VandenBranden; S A Wrighton
Journal:  Drug Metab Dispos       Date:  2000-05       Impact factor: 3.922

8.  Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model.

Authors:  J M Hutzler; M J Hauer; T S Tracy
Journal:  Drug Metab Dispos       Date:  2001-07       Impact factor: 3.922

9.  A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4.

Authors:  M Shou; R Dai; D Cui; K R Korzekwa; T A Baillie; T H Rushmore
Journal:  J Biol Chem       Date:  2000-10-27       Impact factor: 5.157

10.  Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes.

Authors:  J Andrew Williams; Barbara J Ring; Varon E Cantrell; Kristina Campanale; David R Jones; Stephen D Hall; Steven A Wrighton
Journal:  Drug Metab Dispos       Date:  2002-11       Impact factor: 3.922

View more
  18 in total

1.  Inhibitory effects of commonly used herbal extracts on UDP-glucuronosyltransferase 1A4, 1A6, and 1A9 enzyme activities.

Authors:  Mohamed-Eslam F Mohamed; Reginald F Frye
Journal:  Drug Metab Dispos       Date:  2011-06-01       Impact factor: 3.922

2.  Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors.

Authors:  Jin Zhou; Timothy S Tracy; Rory P Remmel
Journal:  Drug Metab Dispos       Date:  2010-10-28       Impact factor: 3.922

Review 3.  First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics.

Authors:  Baojian Wu; Kaustubh Kulkarni; Sumit Basu; Shuxing Zhang; Ming Hu
Journal:  J Pharm Sci       Date:  2011-04-11       Impact factor: 3.534

4.  Enzyme Kinetics of Uridine Diphosphate Glucuronosyltransferases (UGTs).

Authors:  Jin Zhou; Upendra A Argikar; John O Miners
Journal:  Methods Mol Biol       Date:  2021

5.  Fundamentals of Enzyme Kinetics: Michaelis-Menten and Non-Michaelis-Type (Atypical) Enzyme Kinetics.

Authors:  Eleanore Seibert; Timothy S Tracy
Journal:  Methods Mol Biol       Date:  2021

6.  Conjugation of synthetic cannabinoids JWH-018 and JWH-073, metabolites by human UDP-glucuronosyltransferases.

Authors:  Krishna C Chimalakonda; Stacie M Bratton; Vi-Huyen Le; Kan Hui Yiew; Anna Dineva; Cindy L Moran; Laura P James; Jeffery H Moran; Anna Radominska-Pandya
Journal:  Drug Metab Dispos       Date:  2011-07-11       Impact factor: 3.922

7.  A new strategy to rapidly evaluate kinetics of glucuronide efflux by breast cancer resistance protein (BCRP/ABCG2).

Authors:  Baojian Wu; Wen Jiang; Taijun Yin; Song Gao; Ming Hu
Journal:  Pharm Res       Date:  2012-07-03       Impact factor: 4.200

8.  Potential role of UGT1A4 promoter SNPs in anastrozole pharmacogenomics.

Authors:  Vineetha Koroth Edavana; Ishwori B Dhakal; Suzanne Williams; Rosalind Penney; Gunnar Boysen; Aiwei Yao-Borengasser; Susan Kadlubar
Journal:  Drug Metab Dispos       Date:  2013-01-31       Impact factor: 3.922

9.  A potential role for human UDP-glucuronosyltransferase 1A4 promoter single nucleotide polymorphisms in the pharmacogenomics of tamoxifen and its derivatives.

Authors:  Aleksandra K Greer; Centdrika R Dates; Athena Starlard-Davenport; Vineetha K Edavana; Stacie M Bratton; Ishwori B Dhakal; Moshe Finel; Susan A Kadlubar; Anna Radominska-Pandya
Journal:  Drug Metab Dispos       Date:  2014-06-10       Impact factor: 3.922

10.  Metabolic profiling of corylin in vivo and in vitro.

Authors:  Zifei Qin; Shishi Li; Zhihong Yao; Xiaodan Hong; Jinjin Xu; Pei Lin; Guoping Zhao; Frank J Gonzalez; Xinsheng Yao
Journal:  J Pharm Biomed Anal       Date:  2018-03-26       Impact factor: 3.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.